MicroDose Therapeutx (formerly MicroDose Technologies Inc) Begins Phase 1 Trial of MDT-637 for Treatment of Respiratory Syncytial Virus

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--MicroDose Therapeutx, Inc. today announced that the first human subject has been dosed in a Phase 1 clinical trial of MDT-637, MicroDose’s inhalable small molecule antiviral fusion inhibitor for the treatment of respiratory syncytial virus (RSV). This Phase 1 trial follows the reactivation of the United States IND for MDT-637 as re-formulated for delivery using MicroDose’s proprietary dry powder nebulizer.